Cody Joins Forces with PanTera for Actinium-225 Production Facility
At Cody, we’re thrilled to share some exciting news! We’ve been awarded an engineering and equipment manufacturing contract by PanTera to support their groundbreaking efforts in large-scale production of Actinium-225 (Ac-225)—a game-changer in cancer therapy.
Bringing Engineering Expertise to the Fight Against Cancer
Our team at Cody will use our deep expertise in mechanical design, automation, and system integration to create specialized production equipment for PanTera’s cutting-edge Ac-225 production facility in Mol, Belgium.
“We’re honored to partner with PanTera on this revolutionary project,” shares Magnus Skoglund Larsen, Cody’s Chief Business Development Officer. “Our experience in delivering advanced, automated solutions for the pharmaceutical and radiopharmaceutical industries gives us the unique ability to help bring their vision to life—making innovative cancer treatments more accessible worldwide.”
Why Actinium-225 Matters
Actinium-225 is at the forefront of Targeted Alpha Therapy (TAT) for cancer treatment. This remarkable isotope delivers powerful radiation directly to cancer cells, minimizing harm to surrounding healthy tissues. By collaborating with PanTera, Cody is contributing to the large-scale production of Ac-225, which could transform the way cancer is treated globally.
Customized Solutions for a Breakthrough Facility
For this project, Cody will design and build custom production equipment tailored specifically for PanTera’s patented radiochemistry process. Our focus will be on ensuring precision, scalability, and efficiency to meet the unique challenges of Ac-225 production.
“This partnership is a significant milestone for our radiochemistry process. Cody’s expertise in engineering complex radiochemical systems gives us confidence that they will deliver innovative and reliable solutions to meet the growing global demand for Ac-225.” - Samy Bertrand, Chief Technical Officer of PanTera.
A Shared Commitment to Innovation
This collaboration exemplifies Cody’s dedication to advancing medical technology and creating solutions that have a meaningful impact. For us, it’s more than just engineering—it’s about being part of something bigger, contributing to the fight against cancer through innovation.
About PanTera
PanTera originated as a joint venture between IBA and SCK CEN, established to secure the large-scale production of actinium-225 (Ac-225), a promising alpha-emitting radioisotope for targeted cancer therapies. With a Series A funding of €95.6 million and all necessary building blocks available, PanTera is ideally positioned to develop cutting-edge production capabilities to enable the accessibility of innovative cancer treatments based on Ac-225.
PanTera’s production strategy is built on two complementary approaches: an Early Supply production leveraging Thorium-229 decay, which will provide Ac-225 as early as 2025, and a Commercial Supply production utilizing the Ra-226 photonuclear reaction to enable large-scale commercial production by 2028. These initiatives ensure a sustainable and scalable supply chain to meet the growing global demand for Ac-225
Magnus is our Chief Business Development Officer, and with his experience in both mechanical design, automation, project management, and sales, he has full control over what Cody can deliver. He also delves deep into the Machinery Directive, CE marking, and harmonized standards to ensure that what we deliver complies with laws and regulations.
